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Drug-induced acute pancreatitis (DIAP) is an often-neglected entity where the disorder is the conse-
quence of the toxic effects of various agents applied to treat potentially life-threatening conditions, such
as inflammatory bowel disease. Here, we present the case of a male patient with ulcerative colitis with a
history of two episodes of recurrent acute pancreatitis. After excluding other potential causes, we sus-
pected DIAP since the patient received 5-aminosalycilate (5-ASA) prior to the first episode and, one year
later, azathioprine (AZA) prior to the second episode. The causative effect of AZA was confirmed by
performing a re-challenge with a reduced dose. While both episodes of DIAP had a mild disease course,
they were associated with acute relapse of ulcerative colitis. Last seen, the patient was asymptomatic.
With this case, we would like to highlight the importance and diagnostic difficulties of DIAP in the
background of recurrent cases when common etiological factors of acute pancreatitis are excluded.
© 2020 Published by Elsevier B.V. on behalf of IAP and EPC.1. Introduction
Acute pancreatitis (AP) is a leading cause of acute hospitaliza-
tion for gastrointestinal disorders with an incidence varying be-
tween 10 and 100/100,000 inhabitants across countries [1].
Approximately 15e20% of patients with AP develop a severe dis-
ease course which has a mortality of 15% [2]. Biliary pathologies,
alcohol consumption and hyperlipidaemia are in history in more
than >70% of the cases while the rest is usually coined as idiopathic
[2]. However, detailed investigations often raise concerns about the
adverse effects of drugs.
In general, drug-induced AP (DIAP) is considered a rare entity,
accounting for approximately 2e5% of AP episodes worldwide
[3,4]. AZA and 5-ASA, both are part of the basic therapy of ulcerative





alf of IAP and EPC.the development of DIAP. Our recent systematic review revealed 36
case reports regarding 5-ASA-triggered AP in the relevant literature
[3]. In a meta-analysis performed by the Cochrane Collaboration,
three cases of AP were reported from seven randomized controlled
studies including 115 patients treated with AZA [6]. Recurrent DIAP
triggered by either the same or different drugs is rare [7]. In these
cases, patients are at risk for multiple reasons: 1) AP has its own
risk of adverse outcomes, 2) withdrawing the agent suspected in
the background of DIAPmay lead to a burst in disease activity of UC,
and 3) introducing a new treatment has its own risks as well while
the pool of treatment options reduces. With both types of basic
therapy (5-ASA and AZA) one of the most feared adverse reaction is
DIAP [8].
In this paper, we report a case with two episodes of DIAP trig-
gered by 5-ASA and AZA in UC.2. Case presentation
A 31-year old non-compliant patient with left-sided UC (diag-
nosed in 2018, as shown by the timeline in Fig.1A) currently treated
with AZA (1 150mg/day orally), presented to the emergency unit.
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(the Naranjo score was 7; for CT scan, see Fig. 1A). Currently, he
complained of a 3-day history of intermittent colic epigastric
abdominal pain with nausea, vomiting, and bloody diarrhoea
(15e20 times a day). The patient was diagnosedwith an acute flare-
up of UC and suspected recurrent AP, which was confirmed by
serum lipase and amylase activity more than three times greater
than the upper limit of normal (402 and 776 U/L, respectively) and
by characteristic findings on transabdominal ultrasonography and
contrast-enhanced computed tomography (CECT).
The patient was admitted to the inpatient unit of the Division of
Translational Medicine, First Department of Medicine, Medical
School, University of Pecs (Pecs, Hungary). On admission, the pa-
tient had stable cardiopulmonary status with normal hemoglobin
level, the Bedside Index for Severity in Acute Pancreatitis (BISAP)
score was rated 2. Based on complex clinical assessment, the pa-
tient did not require intensive care [9]. We started aggressive
intravenous fluid replacement (10e15 mL/body kg in the first hour,
followed by 3000 ml in the first 24 h) and inserted a thin naso-
gastric tube (10 C h). In order to clarify the etiology of AP, alcoholic
and biliary origins were excluded.
Genetic testing of pancreatitis-associated genes was performed
by Sanger sequencing. We did not find any risk alleles for pancre-
atitis in the investigated genomic regions (all exons of PRSS1,
SPINK1, CTRC, CPA1 genes, and exons 4 and 11 in the CFTR gene). AZA
treatment was assumed to be the cause of AP (DIAP2, Naranjo
score: 10, which is considered a definitive adverse reaction) [8].
Upon conservative treatment, his status significantly improved and
became asymptomatic on the fourth day after admission. Fig. 2
shows the changes in biochemical markers during disease course,
Fig. 1B and C shows two cross-sectional slices from the abdominal
CT scan, demonstrating the radiological features of AP.
We offered a re-challenge with AZA providing strong evidence
about the causative role of the drug since the patient preferred to
continue this treatment [8]. For safety reasons, we reduced theFig. 1. Timeline of the case
1657daily dose from 150 to 50 mg orally. Approximately 6 h after re-
administration, the patient developed abdominal pain (8 of 10 on
a visual analogue score), nausea, vomiting, and re-elevation of
pancreatic enzymes (Fig. 2). Based on the findings (2 out of 3
criteria of AP), we assessed the challenge as positive for AP (DIAP3).
Fluid replacement and immediate enteral feeding were restarted.
After three days, his clinical condition significantly improved along
with the laboratory markers so that oral feeding was restarted
(with a carbohydrate-rich test diet). Since the patient tolerated the
food well, we introduced the regular diet within three days. After
recovery, the severity of AP was rated as mild according to the
Atlanta 2012 criteria [10].
Parallel to the management of AP and after negative stool
culturing, we initiated oral metronidazole (3  500 mg) and oral
methylprednisolone (1  48 mg/day) therapy due to the acute
flare-up of UC, resulting in a significant improvement in his con-
dition and a reduction of stool frequency to 4e5 voids per day.
On discharge, the continuation of metronidazole and tapering of
methylprednisolone were recommended with a medical check-up
appointment 1 month later. Further use of AZA and 5-ASA was
contraindicated, and monthly medical check-ups were arranged.
The inflammatory bowel disease-team (IBD) considered a switch to
biological therapy. Last seen 1 year later, he was asymptomatic.3. Discussion
Herewe reported a case of a mild recurrent DIAP triggered by 5-
ASA in the first (DIAP1) and AZA in the second episode (DIAP2 and
DIAP3) in a young patient with UC. Following the recommendation
of the CARE guideline [11], we performed a systematic search for
cases of recurrent DIAP triggered by two different IBD drugs in
three medical databases (MEDLINE via PubMed, EMBASE and Sco-
pus; details of the search and selection are summarized in
Supplementary Appendix 1). After careful selection, four case re-
ports were identified (Table 1) [7,12e14].and radiology findings.
Fig. 2. Laboratory parameters during the azathioprine-induced acute pancreatitis.
Time period was between May 07,
2019 and 07/15/2019.
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due to 5-ASA and AZA, except one reporting four episodes due to
AZA, 5-ASA, methotrexate, and infliximab [7]. Patients were young
with age ranging from 19 to 47 years. In general, DIAP cases are
younger than AP from other etiologies (supported by our data from
the Hungarian AP Registry) [27]. Unfortunately, these reports were
not detailed enough to establish the disease course of DIAP, except
in one article [12], which describes a similar case where 1-year 5-
ASA treatment was followed by an episode of AZA triggered mild
DIAP. Considering the timing of the development of DIAP, AP
developed within 6 months after the administration of the drugTable 1
Characteristics of the studies reporting on recurrent drug-induced acute pancreatitis.
Author Country Gender Age (year) Type of
Frossard, J.L. et al., 2010 [7]ˣ Switzerland male 47 ulcerativ
colitis
Eland, I.A. et al., 1999 [13] The
Netherlands
female 26 not repo
Toubanakis, Ch. et al., 2003 [12] Greece male 19 ulcerativ
colitis
Glintborg, B. 2000 [14] Danmark unknowna unknowna Crohn’s
disease
Hegyi, J.P. et al., 2020 (the recent
publication)
Hungary male 31 ulcerativ
colitis
ˣ There were two additional DIAPs later after 3-month methotrexate and 3-week inflixim
a We failed to access the paper; data were retrieved from the abstract only.
1658(Table 1).
Both of our cases ended up in recovery; however, DIAP seems
more severe than that of the AP of other etiology (severe cases
accounted for 19.56 vs. 5.63%, respectively; and mortality accoun-
ted for 7.66 vs. 2.25%, respectively) [27].
It is important to note that the articles did not use the drug
response probability scale developed by Naranjo et al. so we cannot
estimate how strong the cause-effect relationship is. In our paper,
the Naranjo score was 10 for DIAP2-3, suggesting a definitive role of
the drug as the trigger of AP. Most evidence on DIAP is based on
anecdotal reports; our knowledge of its true epidemiology isIBD Cause of DIAP1 Cause of DIAP2
e 3-week mesalazine 10-day azathioprine
rted 16-day mesalazine: 3 g/day 4-month azathioprine
e 1-year mesalazine: 2.4 g/day, reduced to
1.2 g/day
7-day azathioprine: 50 mg/
day
mesalazine azathioprine
e 5-week mesalazine: 4 g/day 1-month azathioprine:
150 mg/day
ab therapy DIAP: drug-induced acute pancreatitis IBD: inflammatory bowel disease.
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if there is a tendency for reporting positive or negative findings (in
other words, publication bias may be considerable). The role of
pharmacovigilance networks as well as AP registries with repre-
sentative samples may provide more reliable data on the true
incidence of DIAP.
While the causative role of AZA was well-supported by the
Naranjo score in our case, we must note that the patient received
budesonide treatment together with AZA, raising the potential role
of budesonide in the development of DIAP2. This is, however, very
unlikely because the patient had been treated with budesonide for
6 years between 2012 and 2018 (as indicated in Fig. 1).
DIAP 2 was proven by re-challengewhereas in the case of DIAP1,
the possibility of autoimmune pancreatitis (AIP) may arise. How-
ever, the pancreas morphology based on CT scan did not match the
characteristic traits of AIP. Note that we did not measure IgG4,
being sensitive for type 1 but proven insensitive for type 2 AIP. Type
1 AIP could have been definitively confirmed by pancreatic biopsy;
however, given the mild course of the disease, further diagnostic
workup would not have influenced the therapeutic decisions [15].
DIAP has a continuously increasing incidence from 0.1 to 2% to
higher than 5% [16]. More than 500 drugs have been reported to be
associated with AP, including thiopurine antimetabolites (e.g., AZA
and mercaptopurine, which cases are often termed as thiopurine-
induced acute pancreatitis (TIP)) [12,15]. In general, DIAP is classi-
fied on a spectrum between class I and IV depending on the number
of cases reported and on the results of re-challenge. For instance,
AZA and mercaptopurine belong to Class I drugs and are the most
likely to induce AP [12,16e18].
The group of purine antimetabolite drugs contains AZA, 6-
mercaptopurine (6-MP), and 6-thioguanine [19]. AZA is a prodrug
that is metabolized to 6-MP and by glutathione S-transferase. 6-MP
is transported into cells by the solute carrier and is metabolized via
a series of steps to the 6-thioguanine nucleotides. These metabo-
lites cause immunosuppression into DNA and RNA and by blockade
of Vav-mediated Rac1 activation, which suppresses Rac1 and
thereby T-cell survival and T celleAPC conjugation [20].
Themolecular and cellular pathomechanisms underlying TIP are
currently unknown [21]; nevertheless, the literature distinguishes
theories based onmechanismsmediated via [1] cellular toxicity [2],
toxic metabolites, and [3] immunological responses. (ad 1) Thio-
purine S-methyltransferase (TMPT) is particularly important in the
metabolism of AZA [21,22]. In people with reduced TPMT activity,
both AZA and mercaptopurine break down slowly, and the active
substance 6-thioguanine accumulates, reaches toxic levels, and
causes adverse reactions. In patients with zero TPMT activities, the
risk of severe bone marrow depression is almost 100% [20e22]. In
theory, this mechanism can lead to cellular toxicity in the pancre-
atic parenchyma as well. (ad 2) Findings based on exocrine
pancreatic cells grown from human induced pluripotent stem cells
(iPSC) in vitro support that thiopurine biotransformation can
induce oxidative stress [23]. (ad 3) iPSC-based models are partic-
ularly important in testing the adaptive immunity hypothesis,
which proposes that AZA-related lymphocytes activation occurs in
pancreatic cells. The involvement of the innate immune system by
the activation of macrophages due to lipopolysaccharides was
implicated as well; however, evidence for these theories is still
awaited [21,24,25].
The mechanism of action of aminosalicylic acid is extensively
studied [26]. The active substance of all amino-salicylates is 5-ASA.
This has an anti-inflammatory effect in the intestinal mucosa and,
although the exact mechanism of action remains unclear, several
potential mechanisms are known (e.g., suppression of the release of
anti-inflammatory mediators, such as adhesion molecules,
chemotactic peptides, tumor necrosis factor-a, interleukin-1, or1659leukotrienes, thereby protecting the mucosa from the toxic effects
of substances released during inflammation) [28,29]. However, the
mechanisms by which 5-ASA leads to AP are currently unknown.
The strength of our case report is its novelty (only five recurrent
DIAP cases were reported with different IBD drugs yet). Our case is
well-documented with a strong cause-effect relationship between
AP and drug as indicated by the positive re-challenge and the
Naranjo score. We did not measure the AZA level; however, the re-
challenge (with a lower dose) helps overcome this deficiency. Since
the patient was non-compliant with the treatment of IBD, we do
not know if the relapse was due to missing drug doses or the drug
was ineffective; neither do know yet if the activity of IBD might
contribute to the development of AP.
4. Conclusion
The risk of DIAP, especially that of the recurrent DIAP, is
increased in IBD compared to the general population. Two episodes
in the same patient from different IBD medications are extremely
rarely reported as seen after the literature search. Our case calls
attention to the fact that different IBD medications can cause DIAP
in the same patient leading to drug intolerance and requiring
multiple switches to other therapies. These patients are not only
exposed to the potential harm of the adverse reaction (here: DIAP)
but also they are at risk of relapse during switching.
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